| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.10(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.88 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 8.9 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
123,875 |
414,717 |
427,025 |
1,110,810 |
| Total Sell Value |
$798,994 |
$5,191,225 |
$5,313,647 |
$13,073,359 |
| Total People Sold |
4 |
6 |
6 |
9 |
| Total Sell Transactions |
4 |
10 |
13 |
48 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccourt Thomas A |
President |
• – – |
2020-05-11 |
4 |
AS |
$10.35 |
$17,564 |
D/D |
(1,697) |
319,847 |
|
-10% |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,740 |
107,046 |
|
- |
|
| Kilroy Conor |
SVP, GC & Secretary |
• – – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
22,814 |
129,637 |
|
- |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt.O |
• – – |
2020-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
86,306 |
|
-1% |
|
| Rickard Jason |
SVP, Chief Operating OfficerOf |
• – – |
2020-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
235,090 |
|
-1% |
|
| Kilroy Conor |
SVP, GC & SecretaryOfficer |
• – – |
2020-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
106,823 |
|
-1% |
|
| Dreyfus Andrew |
Director |
– • – |
2020-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,596 |
86,938 |
|
- |
|
| Mccourt Thomas A |
President |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
100,482 |
321,544 |
|
- |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
68,327 |
271,114 |
|
- |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
36,173 |
119,300 |
|
- |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
221,061 |
524,486 |
|
- |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2020-02-24 |
4 |
AS |
$11.25 |
$11 |
D/D |
(1) |
303,425 |
|
-10% |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2020-02-21 |
4 |
AS |
$11.63 |
$92,842 |
D/D |
(7,983) |
303,426 |
|
-13% |
|
| Mccourt Thomas A |
President |
• – – |
2020-02-21 |
4 |
AS |
$11.63 |
$48,579 |
D/D |
(4,177) |
221,062 |
|
-13% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-02-21 |
4 |
AS |
$11.63 |
$45,357 |
D/D |
(3,900) |
83,127 |
|
-13% |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2020-02-21 |
4 |
AS |
$11.63 |
$145,387 |
D/D |
(12,501) |
202,787 |
|
-13% |
|
| Gilbert Halley E |
Chief Admin Officer & SVP |
• – – |
2020-02-21 |
4 |
AS |
$11.63 |
$178,265 |
D/D |
(15,328) |
265,991 |
|
-13% |
|
| Gilbert Halley E |
Chief Admin Officer & SVP |
• – – |
2020-01-31 |
4 |
AS |
$12.05 |
$723,000 |
D/D |
(60,000) |
281,319 |
|
-23% |
|
| Gilbert Halley E |
Chief Admin Officer & SVP |
• – – |
2020-01-31 |
4 |
OE |
$10.02 |
$601,200 |
D/D |
60,000 |
341,319 |
|
- |
|
| Mccourt Thomas A |
President |
• – – |
2020-01-24 |
4 |
AS |
$12.71 |
$254,200 |
D/D |
(20,000) |
225,239 |
|
-24% |
|
| Mccourt Thomas A |
President |
• – – |
2020-01-24 |
4 |
OE |
$10.02 |
$200,400 |
D/D |
20,000 |
245,239 |
|
- |
|
| Currie Mark G |
Director |
– • – |
2020-01-23 |
4 |
AS |
$12.59 |
$755,400 |
D/D |
(60,000) |
549,272 |
|
-22% |
|
| Currie Mark G |
Director |
– • – |
2020-01-23 |
4 |
OE |
$9.12 |
$547,200 |
D/D |
60,000 |
609,272 |
|
- |
|
| Currie Mark G |
Director |
– • – |
2019-12-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
549,272 |
|
- |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2019-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,230 |
86,567 |
|
- |
|
919 Records found
|
|
Page 10 of 37 |
|
|
0.10 (1.55%) 
